IQWiG finds added benefit for AstraZeneca’s Duaklir Genuair for certain patients

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the dossier for Anglo-Swedish pharma major AstraZeneca’s (LSE: AZN) Duaklir Genuair (aclidinium bromide/formoterol fixed dose combination), which is approved in Europe for long-term treatment of adults with chronic obstructive pulmonary disease (COPD).

According to the findings, there is an indication of minor added benefit for adult patients with moderate COPD (grade II). For adults with grade III and fewer than two exacerbations (flare-ups) per year, there is proof of considerable added benefit versus the comparator therapy. In contrast, no conclusions can be drawn on greater or lesser benefit for more severely ill patients from the data presented.

Comparator therapy depends on severity and frequency of exacerbations